Join
Live feed
·
PRReleasevia Quantisnow
Enliven Therapeutics Inc. logo

Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CML

ByQuantisnow·Wall Street's wire, on your screen.
ELVN· Enliven Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ELVN (Enliven Therapeutics Inc.) and more on Quantisnow.